GWS
NBIX icon

Glassman Wealth Services’s Neurocrine Biosciences NBIX Stock Holding History

Glassman Wealth Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-152
Closed -$20K – 1214
2023
Q4 		$20K Hold
152
– – ﹤0.01% 688
2023
Q3 		$17.1K Hold
152
– – ﹤0.01% 697
2023
Q2 		$14.3K Buy
152
+6
+4% +$586 ﹤0.01% 713
2023
Q1 		$14.8K Sell
146
-4
-3% -$416 ﹤0.01% 708
2022
Q4 		$17.9K Buy
150
+4
+3% +$469 ﹤0.01% 689
2022
Q3 		$16K Hold
146
– – ﹤0.01% 678
2022
Q2 		$14K Buy
146
+139
+1,986% +$12.8K ﹤0.01% 723
2022
Q1 		$1K Sell
7
-119
-94% -$10.1K ﹤0.01% 1458
2021
Q4 		$11K Sell
126
-43
-25% -$3.96K ﹤0.01% 765
2021
Q3 		$16K Buy
169
+24
+17% +$2.27K ﹤0.01% 643
2021
Q2 		$14K Hold
145
– – ﹤0.01% 670
2021
Q1 		$14K Buy
145
+18
+14% +$1.89K ﹤0.01% 634
2020
Q4 		$12K Buy
127
+76
+149% +$7.34K ﹤0.01% 678
2020
Q3 		$5K Buy
51
+10
+24% +$1.16K ﹤0.01% 793
2020
Q2 		$5K Buy
41
+32
+356% +$3.54K ﹤0.01% 627
2020
Q1 		$1K Buy
9
+5
+125% +$489 ﹤0.01% 936
2019
Q4 		$0 Sell
4
-3
-43% -$314 ﹤0.01% 1371
2019
Q3 		$1K Buy
7
+3
+75% +$280 ﹤0.01% 881
2019
Q2 		$0 Buy
+4
New +$328 ﹤0.01% 1263

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Glassman Wealth Services's NBIX Position: Q1 2024 in Review

Glassman Wealth Services sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 152 shares — an estimated $20K sold.

Glassman Wealth Services first reported a position in NBIX in Q2 2019 and held it in 19 quarters. The position peaked at $20K in Q4 2023. 591 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Glassman Wealth Services reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 152 Neurocrine Biosciences shares in Q1 2024, an estimated $20K.
  • Glassman Wealth Services first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 19 quarters.
  • Glassman Wealth Services's Neurocrine Biosciences position peaked at $20K in Q4 2023.
  • 591 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.